Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 4Sarcoma 2Breast 2Thoracic 1Lymphoid 1Gynecologic 1

Conditions

Breast Neoplasms 2Sleep Wake Disorders 1Memory Disorders 1Fatigue 1Depression 1Cognitive Dysfunction 1Cognition Disorders 1Anxiety Disorders 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Donepezil × Breast × Clear all
NCT02822573 2023-09-13

Remember

Wake Forest University Health Sciences

Phase 3 Completed
276 enrolled 33 charts
Breast

Breast Neoplasms, Memory Disorders, Cognitive Dysfunction

NCT01466270 2021-10-20

Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction

Wake Forest University Health Sciences

Phase 2 Completed
62 enrolled 12 charts
Breast

Anxiety Disorders, Breast Neoplasms, Cognition Disorders, Depression, Fatigue, Sleep Wake Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡